Lexaria Bioscience Corp. has announced the beginning of its 2026 research and development program designed to broaden pharmaceutical, intellectual property, and business development opportunities through new and improved formulations. The company revealed information on three representative studies that will be primary areas of focus during at least the first three quarters of the calendar year.
CEO Richard Christopher stated that the 2026 R&D program might be the most focused on practical results that the company has ever conducted. These studies are specifically concentrated on increasing the likelihood of pharma industry partnerships and the creation of new intellectual property. Some of this work must intentionally remain obscure at this time since, if successful, it could likely lead to expanded new IP and patent development.
The first study, Human Study GLP-1-H26-7, is expected to be a 5-week parallel group study with primary goals of establishing safety and tolerability, as well as pharmacokinetic evaluation. This study will compare salcaprozate sodium-inclusive DehydraTECH-semaglutide tablet and capsule compositions to the recently launched, commercially available Wegovy semaglutide tablets under fasted pre-dose conditions. The study will evaluate differences between DehydraTECH capsules traditionally optimized for intestinal absorption and DehydraTECH tablets experimentally optimized for primarily stomach absorption.
Study GLP-1-H26-7 will expand upon the findings of Human Pilot Study #1 which delivered exciting PK and safety results with an earlier iteration of SNAC-inclusive DehydraTECH-semaglutide capsules. The new study will be much more robust, with roughly 30 subjects expected to be enrolled in each of the study arms concentrating on the tablet comparisons, and 15 subjects in the capsule study arm. Lexaria is aggressively working with its third-party service providers with the intent of beginning recruitment in this study as early as April, with a final study report expected in Q4 2026.
The company is also progressing rapidly with study design for two animal studies. Animal Study GLP-1-A26-1 is expected to be a large, single-dose study with between 8-11 different arms. Blood samples are expected to be drawn over an 8-24-hour post-dose period to quantify the PK performance of the active ingredients. Brain samples will also be taken since DehydraTECH has, in the past, evidenced apparent superior absorption of active ingredients into brain tissue, an area of intense interest due to the fact that GLP-1 drug performance is increasingly understood to include or even depend upon involvement of brain neurochemistry.
Animal Study GLP-1-A26-2 is expected to be a large, single-dose study with between 14-18 different arms. This study will be focused on the delivery of DehydraTECH enhanced retatrutide and amycretin, both GLP-1 drugs that Lexaria has never studied before. The inclusion of retatrutide will mark the first time that the company has worked with a triple agonist which targets GLP-1, glucose-dependent insulinotropic polypetide and glucagon receptors. Some of the study arms will be comparing the PK performance of test articles placed endoscopically in the intestine versus being swallowed thus targeting the stomach, in order to compare and contrast formulation functionality and performance in these distinct drug delivery dosing regions gastrointestinally.
Both animal studies are anticipated to begin by Q2 2026 with final study reports expected near the end of Q3 2026. Each of the studies will be conducted by independent third-party service providers and individually announced with additional details once they are ready to proceed. Additional R&D work, not yet disclosed, may be completed during 2026.
For business and technology leaders, Lexaria's 2026 R&D program represents a strategic move in the competitive GLP-1 drug delivery market. The focus on creating new intellectual property through these studies could position the company for valuable licensing agreements or partnerships with major pharmaceutical companies. The research into brain absorption enhancement addresses a critical aspect of GLP-1 drug efficacy that could differentiate Lexaria's technology in a crowded marketplace. The company's approach to testing both established and novel GLP-1 formulations demonstrates a comprehensive strategy to capture value across the expanding weight loss and diabetes treatment markets.
